DB18440InvestigationalProtein Based Therapies
Vurolenatide is a recombinant fusion protein comprising exenatide and XTEN.
- Also known as
- GLP-1-XTEN · L-HISTIDYLGLYCYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-.ALPHA.-ASPARTYL-L-LEUCYL-L-SERYL-L-LYSYL-L-GLUTAMINYL-L-METHIONYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-ALANYL-L-VALYL-L-ARGINYL-L-LEUCYL-L-PHE · XTEN-GLP1
- Code names
- NB-1001 · NM-002
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Vurolenatide, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account